293 related articles for article (PubMed ID: 30253078)
1. Targeting immunotherapy for bladder cancer using anti-CD3× B7-H3 bispecific antibody.
Ma W; Ma J; Ma P; Lei T; Zhao M; Zhang M
Cancer Med; 2018 Oct; 7(10):5167-5177. PubMed ID: 30253078
[TBL] [Abstract][Full Text] [Related]
2. B7-H3 as a promising target for cytotoxicity T cell in human cancer therapy.
Ma J; Ma P; Zhao C; Xue X; Han H; Liu C; Tao H; Xiu W; Cai J; Zhang M
Oncotarget; 2016 May; 7(20):29480-91. PubMed ID: 27121051
[TBL] [Abstract][Full Text] [Related]
3. Bispecific anti-CD3 x anti-B7-H3 antibody mediates T cell cytotoxic ability to human melanoma in vitro and in vivo.
Ma J; Shang T; Ma P; Sun X; Zhao J; Sun X; Zhang M
Invest New Drugs; 2019 Oct; 37(5):1036-1043. PubMed ID: 30706335
[TBL] [Abstract][Full Text] [Related]
4. T cell cytotoxicity toward hematologic malignancy via B7-H3 targeting.
Sun X; Yu Y; Ma L; Xue X; Gao Z; Ma J; Zhang M
Invest New Drugs; 2020 Jun; 38(3):722-732. PubMed ID: 31267380
[TBL] [Abstract][Full Text] [Related]
5. Targeting bladder cancer using activated T cells armed with bispecific antibodies.
Ma J; Ge J; Xue X; Xiu W; Ma P; Sun X; Zhang M
Oncol Rep; 2018 Mar; 39(3):1245-1252. PubMed ID: 29328392
[TBL] [Abstract][Full Text] [Related]
6. Targeting immunotherapy for bladder cancer by using anti-CD3 × CD155 bispecific antibody.
Ma W; Ma J; Lei T; Zhao M; Zhang M
J Cancer; 2019; 10(21):5153-5161. PubMed ID: 31602268
[TBL] [Abstract][Full Text] [Related]
7. The bispecific anti-CD3 × anti-CD155 antibody mediates T cell immunotherapy for human prostate cancer.
Zhao H; Ma J; Lei T; Ma W; Zhang M
Invest New Drugs; 2019 Oct; 37(5):810-817. PubMed ID: 30374653
[TBL] [Abstract][Full Text] [Related]
8. B7-H6 as an efficient target for T cell-induced cytotoxicity in haematologic malignant cells.
Sun X; Zhao J; Ma L; Sun X; Ge J; Yu Y; Ma J; Zhang M
Invest New Drugs; 2021 Feb; 39(1):24-33. PubMed ID: 32770284
[TBL] [Abstract][Full Text] [Related]
9. HER2 as a promising target for cytotoxicity T cells in human melanoma therapy.
Ma J; Han H; Liu D; Li W; Feng H; Xue X; Wu X; Niu G; Zhang G; Zhao Y; Liu C; Tao H; Gao B
PLoS One; 2013; 8(8):e73261. PubMed ID: 24015299
[TBL] [Abstract][Full Text] [Related]
10. Anti-CD3 × anti-GD2 bispecific antibody redirects T-cell cytolytic activity to neuroblastoma targets.
Yankelevich M; Kondadasula SV; Thakur A; Buck S; Cheung NK; Lum LG
Pediatr Blood Cancer; 2012 Dec; 59(7):1198-205. PubMed ID: 22707078
[TBL] [Abstract][Full Text] [Related]
11. Human T cells armed with Her2/neu bispecific antibodies divide, are cytotoxic, and secrete cytokines with repeated stimulation.
Grabert RC; Cousens LP; Smith JA; Olson S; Gall J; Young WB; Davol PA; Lum LG
Clin Cancer Res; 2006 Jan; 12(2):569-76. PubMed ID: 16428502
[TBL] [Abstract][Full Text] [Related]
12. Targeting and killing of glioblastoma with activated T cells armed with bispecific antibodies.
Zitron IM; Thakur A; Norkina O; Barger GR; Lum LG; Mittal S
BMC Cancer; 2013 Feb; 13():83. PubMed ID: 23433400
[TBL] [Abstract][Full Text] [Related]
13. Bispecific anti-CD3 x anti-HER2 antibody mediates T cell cytolytic activity to HER2-positive colorectal cancer in vitro and in vivo.
Han H; Ma J; Zhang K; Li W; Liu C; Zhang Y; Zhang G; Ma P; Wang L; Zhang G; Tao H; Gao B
Int J Oncol; 2014 Dec; 45(6):2446-54. PubMed ID: 25242665
[TBL] [Abstract][Full Text] [Related]
14. T cells armed with anti-CD3 x anti-CD20 bispecific antibody enhance killing of CD20+ malignant B cells and bypass complement-mediated rituximab resistance in vitro.
Gall JM; Davol PA; Grabert RC; Deaver M; Lum LG
Exp Hematol; 2005 Apr; 33(4):452-9. PubMed ID: 15781336
[TBL] [Abstract][Full Text] [Related]
15. Use of anti-CD3 x anti-HER2/neu bispecific antibody for redirecting cytotoxicity of activated T cells toward HER2/neu+ tumors.
Sen M; Wankowski DM; Garlie NK; Siebenlist RE; Van Epps D; LeFever AV; Lum LG
J Hematother Stem Cell Res; 2001 Apr; 10(2):247-60. PubMed ID: 11359672
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of effector CD8+ T-cell function by tumour-associated B7-H3 and modulation of its counter-receptor triggering receptor expressed on myeloid cell-like transcript 2 at tumour sites.
Kobori H; Hashiguchi M; Piao J; Kato M; Ritprajak P; Azuma M
Immunology; 2010 Jul; 130(3):363-73. PubMed ID: 20141543
[TBL] [Abstract][Full Text] [Related]
17. Preclinical studies comparing different bispecific antibodies for redirecting T cell cytotoxicity to extracellular antigens on prostate carcinomas.
Lum HE; Miller M; Davol PA; Grabert RC; Davis JB; Lum LG
Anticancer Res; 2005; 25(1A):43-52. PubMed ID: 15816517
[TBL] [Abstract][Full Text] [Related]
18. A bispecific T cell engager targeting Glypican-1 redirects T cell cytolytic activity to kill prostate cancer cells.
Lund ME; Howard CB; Thurecht KJ; Campbell DH; Mahler SM; Walsh BJ
BMC Cancer; 2020 Dec; 20(1):1214. PubMed ID: 33302918
[TBL] [Abstract][Full Text] [Related]
19. Anti-CD3 x anti-epidermal growth factor receptor (EGFR) bispecific antibody redirects T-cell cytolytic activity to EGFR-positive cancers in vitro and in an animal model.
Reusch U; Sundaram M; Davol PA; Olson SD; Davis JB; Demel K; Nissim J; Rathore R; Liu PY; Lum LG
Clin Cancer Res; 2006 Jan; 12(1):183-90. PubMed ID: 16397041
[TBL] [Abstract][Full Text] [Related]
20. Anti-CD3 x anti-HER2 bispecific antibody effectively redirects armed T cells to inhibit tumor development and growth in hormone-refractory prostate cancer-bearing severe combined immunodeficient beige mice.
Davol PA; Smith JA; Kouttab N; Elfenbein GJ; Lum LG
Clin Prostate Cancer; 2004 Sep; 3(2):112-21. PubMed ID: 15479495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
